Allogene Therapeutics
ALLO
180 hedge funds and large institutions have $835M invested in Allogene Therapeutics in 2022 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 72 increasing their positions, 45 reducing their positions, and 30 closing their positions.
62% more call options, than puts
Call options by funds: $1.24M | Put options by funds: $764K
60% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 45
10% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 30
4.06% more ownership
Funds ownership: 60.21% → 64.27% (+4.1%)
2% more funds holding
Funds holding: 177 → 180 (+3)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
35% less capital invested
Capital invested by funds: $1.28B → $835M (-$445M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$36.1M |
| 2 |
Goldman Sachs
New York
|
+$11.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.6M |
| 4 |
Renaissance Technologies
New York
|
+$10.2M |
| 5 |
Two Sigma Investments
New York
|
+$7.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$39.5M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$19.4M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$14.2M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$10.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.83M |
ALLO Hedge Fund Activity: Q1 2022 in Review
180 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q1 2022, worth a combined $835M — down 35% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ALLO positions and 30 closed out — a net gain of 3 holders — while 72 added to existing stakes and 45 trimmed.
The largest buyer was State Street, adding an estimated $36.1M. The largest seller was Casdin Capital, exiting entirely with an estimated $39.5M sold.
- 180 institutional investors held Allogene Therapeutics (ALLO) as of Q1 2022, up from 177 in Q4 2021.
- Funds reported $835M of Allogene Therapeutics stock for Q1 2022, down 35% quarter-over-quarter.
- 33 funds opened new Allogene Therapeutics positions in Q1 2022 and 30 closed out, a net change of +3 holders.
- The largest Allogene Therapeutics buyer in Q1 2022 was State Street, an estimated $36.1M added.
- The largest Allogene Therapeutics seller in Q1 2022 was Casdin Capital, an estimated $39.5M sold.
Based on aggregated 13F filings for Q1 2022.